- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03588975
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee (PEAK)
A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phase 3 Clinical Study of the Safety and Efficacy of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a 2-year prospective, multicenter, randomized, open-label, parallel group clinical trial; a total of 45 patients, ages 10 to 17 years, will be randomized to receive a 1-time treatment with MACI or microfracture (2:1, 30 MACI:15 microfracture).
After meeting screening criteria at the initial visit, all patients will have a screening arthroscopy to further assess study eligibility. During the screening arthroscopy, patients will be further evaluated against entry criteria. Cartilage lesion size will be measured prior to any cartilage repair procedure and randomization. All patients who meet the eligibility criteria and are considered suitable for treatment in the study will have a cartilage biopsy taken prior to randomization to study treatment. Eligible patients will be randomized during the screening arthroscopy procedure to receive either MACI or microfracture treatment. Patients randomized to microfracture will undergo the procedure during the screening arthroscopy.
All biopsied tissue will be sent to the Vericel manufacturing facility in Cambridge, Massachusetts, where the sample will be processed to isolate the autologous chondrocytes. Cells from patients randomized to the MACI group will be used in the preparation of the MACI implant; cells from patients randomized to the microfracture group will be cryopreserved.
Patients randomized to treatment with MACI will return within 12 weeks of the screening arthroscopy to undergo the chondrocyte implantation procedure via arthrotomy. Patients are to follow a recommended postoperative rehabilitation program and compliance with the rehabilitation schedule will be monitored.
Patients will be followed post-study treatment for 2 years (104 Weeks).
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Mikhail E Chkolnik, MD
- Phone Number: 484-387-2257
- Email: mchkolnik@vcel.com
Study Contact Backup
- Name: Kristin M Tripp, BS
- Email: ktripp@vcel.com
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Recruiting
- Stanford University
-
Sacramento, California, United States, 95817
- Recruiting
- University of California Davis Health
-
Sacramento, California, United States, 95817
- Recruiting
- Shriner's Hospital for Children Northern California
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Recruiting
- Ochsner Sports Medicine Institute
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Recruiting
- Johns Hopkins Outpatient Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- Recruiting
- University of Michigan
-
-
Ohio
-
Akron, Ohio, United States, 44308
- Recruiting
- Akron Children's Hospital
-
Columbus, Ohio, United States, 43202
- Recruiting
- The Ohio State University Jameson Crane Sports Medicine Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Penn Sports Medicine Center
-
-
Texas
-
Houston, Texas, United States, 77094
- Not yet recruiting
- Texas Children's Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53201
- Recruiting
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Symptomatic cartilage or osteochondral defects
- One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and/or trochlea amenable to treatment with the surgical procedure determined at randomization (MACI or microfracture).
- At least 1 defect size ≥1.5 cm2 on the femoral condyles and/or the trochlea; defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft.
- Stable target knee (i.e., anterior and posterior cruciate ligaments should be free of laxity as well as stable and intact). Ligament repair or reconstruction procedures are allowed prior to screening arthroscopy.
- Intact meniscus or partial meniscus (at least 50% of functional meniscus remaining) in the target knee.
Exclusion Criteria:
- Any surgery on the target knee joint within 6 months prior to Screening (not including diagnostic arthroscopy)
- ICRS Grade III or IV chondral or unsalvageable osteochondral defects located on the patella or tibia or any lesion that is bipolar to the index lesion
- Concomitant inflammatory disease or other conditions that affects the joints (eg, rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis)
- Known history of septic arthritis in the index knee joint
- Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin
- Females who are pregnant or lactating
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MACI
autologous cultured chondrocytes on porcine collagen membrane
|
autologous cultured chondrocytes on porcine collagen membrane
|
Active Comparator: microfracture
surgical procedure
|
Arthroscopic microfracture treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Patients Who Achieve at Least a 10-point Improvement From Baseline in KOOS-Child Pain and Function (Sports and Recreational Activities) Scores
Time Frame: Baseline and Week 104
|
A responder is defined as a participant with at least a 10-point change (improvement) in both the KOOS-Child Pain and Function (Sports and Recreational activities) scores from Baseline scores.
The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the patients' opinion of their knee and associated problems.
KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL).
|
Baseline and Week 104
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in KOOS-Child subscores
Time Frame: Baseline and Week 104
|
The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the patients' opinion of their knee and associated problems.
KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL).
|
Baseline and Week 104
|
Change from Baseline in KOOS-Child subscores
Time Frame: Baseline and Week 52
|
The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the patients' opinion of their knee and associated problems.
KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL).
|
Baseline and Week 52
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Emergent Adverse Events
Time Frame: Week 104
|
A treatment emergent untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.
|
Week 104
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jonathan Hopper, Vericel Corporation
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 55-1702-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chondral Defect
-
TRB Chemedica AGCompletedFocal Chondral Defect in Femoro-tibial Compartment of the Knee JointGermany
-
Jordi Villalba ModolUnknownChondral Defect | Osteochondral DefectSpain
-
Bergen Orthopedic Study GroupCompleted
-
Centre Hospitalier Universitaire VaudoisLee Ann LAURENT APPLEGATE; Virginie PHILIPPENot yet recruitingChondral Defect | Articular Cartilage Defect | OsteochondritisSwitzerland
-
TBF Genie TissulaireTerminatedOsteochondral Defect | Knee ChondralBelgium
-
Centre Hospitalier Universitaire VaudoisRecruitingChondral Defect | Articular Cartilage Defect | OsteochondritisSwitzerland
-
Geistlich Pharma AGWithdrawnChondral Defect | Osteochondral Lesion of Talus | MicrofractureUnited Kingdom
-
University Hospital, BrestInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedKnee Chondral or Osteochondral DefectFrance
-
Oligo Medic Pty LtdMobius Medical Pty Ltd.RecruitingChondral Defect | Articular Cartilage Disorder of Knee | Articular Cartilage DefectAustralia, Canada
-
UMC UtrechtRecruitingOsteoarthritis, Knee | Chondral Defect | Osteochondritis Dissecans | Osteochondral Defect | Knee PathologyNetherlands
Clinical Trials on MACI
-
Vericel CorporationCompletedArticular Cartilage DefectNetherlands, Norway, France, Czechia, Sweden, Poland, United Kingdom
-
Vericel CorporationCompletedArticular Cartilage DefectsNorway, Netherlands, France, Czechia, Poland, Sweden, United Kingdom
-
Keele UniversityRobert Jones and Agnes Hunt Orthopaedic and District NHS TrustCompletedCartilage Injury | Cartilage DamageUnited Kingdom